NDLI: Advances in treatment of chronic myelogenous leukemia--new treatment options with tyrosine kinase inhibitors.

Please wait, while we are loading the content...

Advances in treatment of chronic myelogenous leukemia--new treatment options with tyrosine kinase inhibitors.

Content Provider	Scilit
Author	Santos, Fabio P. S. Ravandi, Farhad
Copyright Year	2009
Description	Journal: Leukemia & Lymphoma Imatinib is considered standard therapy for patients with chronic myelogenous leukemia (CML), inducing a high rate of hematologic and cytogenetic responses. Despite these excellent results, several patients develop resistance to imatinib. Mechanisms of resistance are varied and include BCR-ABL1 kinase domain mutations, decreased entry of imatinib into cells, acquisition of secondary genetic changes and activation of alternate signaling pathways. Second-generation tyrosine kinase inhibitors (TKI) (dasatinib, nilotinib) were developed as an alternative for patients that develop resistance or are intolerant to imatinib. Dasatinib is a dual Abl/Src kinase TKI that is structurally unrelated to imatinib and is approved for therapy of all phases of CML in patients who are resistant or intolerant to imatinib. Nilotinib is a compound related to imatinib that has greater specificity and improved binding characteristics, and has clinical activity in the setting of imatinib failure. Resistance to multiple TKIs does occur, particularly in patients with the T315I mutation. Several new agents are in development including new TKIs, aurora kinase inhibitors and homoharringtonine.
Related Links	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4109296/pdf https://www.tandfonline.com/doi/pdf/10.3109/10428190903383427
Ending Page	26
Page Count	11
Starting Page	16
ISSN	10428194
e-ISSN	10292403
DOI	10.3109/10428190903383427
Journal	Leukemia & Lymphoma
Issue Number	sup2
Volume Number	50
Language	English
Publisher	Informa UK Limited
Publisher Date	2009-12-17
Access Restriction	Open
Subject Keyword	Journal: Leukemia & Lymphoma Chronic Myelogenous Leukemia
Content Type	Text
Subject	Hematology Cancer Research Oncology

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in